• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

贝叶斯设计标准:计算、比较及其在药代动力学和药效学模型中的应用。

Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.

作者信息

Merlé Y, Mentré F

机构信息

INSERM U194, CHU Pitié-Salpêtrière, Paris, France.

出版信息

J Pharmacokinet Biopharm. 1995 Feb;23(1):101-25. doi: 10.1007/BF02353788.

DOI:10.1007/BF02353788
PMID:8576840
Abstract

In this paper 3 criteria to design experiments for Bayesian estimation of the parameters of nonlinear models with respect to their parameters, when a prior distribution is available, are presented: the determinant of the Bayesian information matrix, the determinant of the pre-posterior covariance matrix, and the expected information provided by an experiment. A procedure to simplify the computation of these criteria is proposed in the case of continuous prior distributions and is compared with the criterion obtained from a linearization of the model about the mean of the prior distribution for the parameters. This procedure is applied to two models commonly encountered in the area of pharmacokinetics and pharmacodynamics: the one-compartment open model with bolus intravenous single-dose injection and the Emax model. They both involve two parameters. Additive as well as multiplicative gaussian measurement errors are considered with normal prior distributions. Various combinations of the variances of the prior distribution and of the measurement error are studied. Our attention is restricted to designs with limited numbers of measurements (1 or 2 measurements). This situation often occurs in practice when Bayesian estimation is performed. The optimal Bayesian designs that result vary with the variances of the parameter distribution and with the measurement error. The two-point optimal designs sometimes differ from the D-optimal designs for the mean of the prior distribution and may consist of replicating measurements. For the studied cases, the determinant of the Bayesian information matrix and its linearized form lead to the same optimal designs. In some cases, the pre-posterior covariance matrix can be far from its lower bound, namely, the inverse of the Bayesian information matrix, especially for the Emax model and a multiplicative measurement error. The expected information provided by the experiment and the determinant of the pre-posterior covariance matrix generally lead to the same designs except for the Emax model and the multiplicative measurement error. Results show that these criteria can be easily computed and that they could be incorporated in modules for designing experiments.

摘要

本文提出了3条准则,用于在有先验分布的情况下,针对非线性模型的参数设计贝叶斯估计实验:贝叶斯信息矩阵的行列式、先验后验协方差矩阵的行列式以及实验提供的期望信息。针对连续先验分布的情况,提出了一种简化这些准则计算的方法,并将其与通过模型关于参数先验分布均值的线性化得到的准则进行了比较。该方法应用于药代动力学和药效学领域常见的两个模型:大剂量静脉单次注射单室开放模型和Emax模型。这两个模型都涉及两个参数。考虑了具有正态先验分布的加性和乘性高斯测量误差。研究了先验分布方差和测量误差的各种组合。我们的注意力仅限于测量次数有限(1次或2次测量)的设计。在实际进行贝叶斯估计时,这种情况经常发生。得到的最优贝叶斯设计随参数分布的方差和测量误差而变化。两点最优设计有时与参数先验分布均值的D最优设计不同,并且可能包括重复测量。对于所研究的情况,贝叶斯信息矩阵的行列式及其线性化形式导致相同的最优设计。在某些情况下,先验后验协方差矩阵可能远偏离其下限,即贝叶斯信息矩阵的逆,特别是对于Emax模型和乘性测量误差。除了Emax模型和乘性测量误差外,实验提供的期望信息和先验后验协方差矩阵的行列式通常导致相同的设计。结果表明,这些准则易于计算,并且可以纳入实验设计模块中。

相似文献

1
Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.贝叶斯设计标准:计算、比较及其在药代动力学和药效学模型中的应用。
J Pharmacokinet Biopharm. 1995 Feb;23(1):101-25. doi: 10.1007/BF02353788.
2
Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.药代动力学-药效学模型线性化对群体信息矩阵准确性和最优设计的影响。
J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):363-88. doi: 10.1023/a:1011534830530.
3
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.参数和非参数总体方法:它们在分析临床数据集和两项蒙特卡罗模拟研究中的比较性能。
Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003.
4
Stochastic optimization algorithms of a Bayesian design criterion for Bayesian parameter estimation of nonlinear regression models: application in pharmacokinetics.用于非线性回归模型贝叶斯参数估计的贝叶斯设计准则的随机优化算法:在药代动力学中的应用
Math Biosci. 1997 Aug;144(1):45-70. doi: 10.1016/s0025-5564(97)00017-5.
5
Robust optimal design for the estimation of hyperparameters in population pharmacokinetics.群体药代动力学中超参数估计的稳健优化设计。
J Pharmacokinet Biopharm. 1998 Dec;26(6):689-716. doi: 10.1023/a:1020703007613.
6
Evaluation of Bayesian estimation of pharmacokinetic parameters.药代动力学参数的贝叶斯估计评估。
Ther Drug Monit. 2005 Feb;27(1):18-24. doi: 10.1097/00007691-200502000-00005.
7
D-optimal designs of mean-covariance models for longitudinal data.纵向数据均值-协方差模型的 D-最优设计。
Biom J. 2021 Jun;63(5):1072-1085. doi: 10.1002/bimj.202000129. Epub 2021 Feb 19.
8
Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.药代动力学模型的贝叶斯最优设计:对不确定性的敏感性
J Biopharm Stat. 2007;17(5):851-67. doi: 10.1080/10543400701514007.
9
PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.PFIM 4.0,一个用于非线性混合效应模型设计评估和优化的扩展 R 程序。
Comput Methods Programs Biomed. 2018 Mar;156:217-229. doi: 10.1016/j.cmpb.2018.01.008. Epub 2018 Jan 11.
10
Optimal sampling times for Bayesian estimation of the pharmacokinetic parameters of nortriptyline during therapeutic drug monitoring.治疗药物监测期间去甲替林药代动力学参数贝叶斯估计的最佳采样时间。
J Pharmacokinet Biopharm. 1999 Feb;27(1):85-101. doi: 10.1023/a:1020634813296.

引用本文的文献

1
The Use of Microdosing for In vivo Phenotyping of Cytochrome P450 Enzymes: Where Do We Stand? A Narrative Review.微量给药在细胞色素 P450 酶体内表型研究中的应用:我们处于什么位置? 一篇叙述性综述。
Eur J Drug Metab Pharmacokinet. 2024 Jul;49(4):407-418. doi: 10.1007/s13318-024-00896-2. Epub 2024 Apr 30.
2
"De-Shrinking" EBEs: The Solution for Bayesian Therapeutic Drug Monitoring.“去收缩”的群体药代动力学个体参数估计:贝叶斯治疗药物监测的解决方案
Clin Pharmacokinet. 2022 May;61(5):749-757. doi: 10.1007/s40262-021-01105-y. Epub 2022 Feb 4.
3
Experiment design for nonparametric models based on minimizing Bayes Risk: application to voriconazole¹.

本文引用的文献

1
Computer-assisted individual estimation of radioiodine thyroid uptake in Grave's disease.计算机辅助的格雷夫斯病中放射性碘甲状腺摄取的个体估计。
Comput Methods Programs Biomed. 1993 May;40(1):33-41. doi: 10.1016/0169-2607(93)90047-o.
2
Pharmacokinetic and pharmacodynamic data and models in clinical trials.临床试验中的药代动力学和药效学数据及模型。
Eur J Drug Metab Pharmacokinet. 1993 Jan-Mar;18(1):61-76. doi: 10.1007/BF03220009.
3
Designing an optimal experiment for Bayesian estimation: application to the kinetics of iodine thyroid uptake.
基于最小化贝叶斯风险的非参数模型的实验设计:伏立康唑的应用¹
J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):95-111. doi: 10.1007/s10928-016-9498-5. Epub 2016 Dec 1.
4
A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.基于最大后验贝叶斯估计的五探针表型鸡尾酒有限采样策略。
Eur J Clin Pharmacol. 2016 Jan;72(1):39-51. doi: 10.1007/s00228-015-1953-5.
5
Inter occasion variability in individual optimal design.个体最优设计中的不同场合间变异性。
J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):735-50. doi: 10.1007/s10928-015-9449-6. Epub 2015 Oct 1.
6
Powers of the likelihood ratio test and the correlation test using empirical bayes estimates for various shrinkages in population pharmacokinetics.应用经验贝叶斯估计对群体药代动力学中各种收缩进行似然比检验和相关检验的功效。
CPT Pharmacometrics Syst Pharmacol. 2014 Apr 9;3(4):e109. doi: 10.1038/psp.2014.5.
7
Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome.先验信息、设计和不可检测数据对丙型肝炎治疗结果个体参数估计和预测的影响。
CPT Pharmacometrics Syst Pharmacol. 2013 Jul 17;2(7):e56. doi: 10.1038/psp.2013.31.
8
Prediction of shrinkage of individual parameters using the bayesian information matrix in non-linear mixed effect models with evaluation in pharmacokinetics.利用贝叶斯信息矩阵预测非线性混合效应模型中个体参数的收缩,在药代动力学中进行评估。
Pharm Res. 2013 Sep;30(9):2355-67. doi: 10.1007/s11095-013-1079-3. Epub 2013 Jun 7.
9
Robust population pharmacokinetic experiment design.稳健的群体药代动力学实验设计。
J Pharmacokinet Pharmacodyn. 2005 Feb;32(1):33-64. doi: 10.1007/s10928-005-2102-z.
10
Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.白血病患儿中依托泊苷和依托泊苷儿茶酚的有限及优化采样策略
J Pharmacokinet Pharmacodyn. 2002 Apr;29(2):171-88. doi: 10.1023/a:1019755608555.
Stat Med. 1994 Jan 30;13(2):185-96. doi: 10.1002/sim.4780130209.
4
The use of prior distributions in the design of experiments for parameter estimation in non-linear situations: multiresponse case.先验分布在非线性情况下参数估计实验设计中的应用:多响应情形
Biometrika. 1967 Dec;54(3):662-5.
5
An application of population pharmacokinetics to the clinical use of cyclosporine in bone marrow transplant patients.群体药代动力学在骨髓移植患者环孢素临床应用中的应用。
Transplant Proc. 1988 Apr;20(2 Suppl 2):466-70.
6
Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.群体药效学设计:药代动力学数据和群体分析的价值
J Pharmacokinet Biopharm. 1991 Jun;19(3):333-53. doi: 10.1007/BF03036255.
7
Bayesian parameter estimation and population pharmacokinetics.
Clin Pharmacokinet. 1992 Jun;22(6):447-67. doi: 10.2165/00003088-199222060-00004.
8
APIS: a software for model identification, simulation and dosage regimen calculations in clinical and experimental pharmacokinetics.
Comput Methods Programs Biomed. 1992 Aug;38(4):227-39. doi: 10.1016/0169-2607(92)90103-e.